IP Library › Granted Patent US 12,710,432
Granted Patent B1
US 12,710,432 · App. 17/690,877 · Granted Aug 18, 2026

Methods of diagnosing and treating based on site-specific tau phosphorylation

Inventors: Randall Bateman (St. Louis, MO); Nicolas Barthelemy (St. Louis, MO); Eric McDade (St. Louis, MO)
Assignee: Washington University
G01N33/6896
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,710,432
App. No.
17/690,877
Filed
Mar 9, 2022
Granted
Aug 18, 2026
Kind
B1
Art Unit
1644
USPC
424/85.1
Abstract

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Claims (30)

1 . A method for selecting a therapeutic agent for a subject in need thereof, the method comprising

(a) measuring in a biological sample obtained from the subject (i) Nfl, and (ii) tau phosphorylation at T205 and T181, at T205 and T217, or at T205, T181, and T217; and

(b) administering to the subject a therapeutic agent, wherein

(i) the biological sample obtained from the subject contains tau phosphorylation at T181 and/or tau phosphorylation at T217 that significantly deviates above the mean of a control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF, and tau phosphorylation at T205 that does not significantly deviate from the mean of the control population, and an amount of Nfl that does not significantly deviate from the mean of the control population, and the therapeutic agent prevents amyloid deposition from increasing in the subject or reduces the existing plaque load in the subject, or

the biological sample obtained from the subject contains tau phosphorylation at T181 and/or tau phosphorylation at T217 that significantly deviates above the mean of a control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF, and tau phosphorylation at T205 that significantly deviates above the mean of the control population, and an amount of Nfl that significantly deviates above the mean of the control population, and the therapeutic agent prevents amyloid deposition from increasing in the subject, reduces the existing plaque load in the subject, prevents tau aggregation in the subject, or targets neurofibrillary tangles in the subject,

wherein the biological sample is a CSF or blood sample, and

wherein the significant deviation of tau phosphorylation at T205 and/or T217 in (b)(1) or (b)(ii) is indicative that the therapeutic agent is to be selected from a cholinesterase inhibitor, an N-methyl D-aspartate (NMDA) antagonist, an antidepressant, a gamma-secretase inhibitor, a beta-secretase inhibitor, an anti-Aβ antibody, an anti-tau antibody, an antagonist of the serotonin receptor 6, a p38alpha MAPK inhibitor, recombinant granulocyte macrophage colony-stimulating factor, a passive immunotherapy, an active vaccine, a tau protein aggregation inhibitor, an anti-inflammatory agent, a phosphodiesterase 9A inhibitor, a sigma-1 receptor agonist, a kinase inhibitor, a phosphatase activator, a phosphatase inhibitor, a selective inhibitor of APP production, an angiotensin receptor blocker, a CB1 and/or CB2 endocannabinoid receptor partial agonist, a β-2 adrenergic receptor agonist, a nicotinic acetylcholine receptor agonist, a 5-HT2A inverse agonist, an alpha-2c adrenergic receptor antagonist, a 5-HT 1A and 1D receptor agonist, a glutaminyl-peptide cyclotransferase inhibitor, a selective inhibitor of APP production, a monoamine oxidase B inhibitor, a glutamate receptor antagonist, an AMPA receptor agonist, a nerve growth factor stimulant, a HMG-CoA reductase inhibitor, a neurotrophic agent, a muscarinic M1 receptor agonist, a GABA receptor modulator, a PPAR-gamma agonist, a microtubule protein modulator, a calcium channel blocker, an antihypertensive agent, a statin, or any combination thereof.

2 . The method of claim 1 , wherein the biological sample is enriched for tau with an anti-tau epitope binding agent, and/or enriched for Nfl with an anti-Nfl epitope binding agent.

3 . The method of claim 1 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(i) or b(ii) is 1.5 σ or above,

wherein σ is the standard deviation defined by the normal distribution of tau phosphorylation at the residue, as measured in the control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF.

4 . The method of claim 3 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(i) or b(ii) is 2.0σ or above.

5 . The method of claim 1 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(i) is 1.5 σ or above, and the deviation of tau phosphorylation at T205 from the mean in (b)(1) is below 1.5 σ,

wherein σ is the standard deviation defined by the normal distribution of tau phosphorylation at the residue, as measured in the control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF.

6 . The method of claim 5 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(i) is 2.0 σ or above, and the deviation of tau phosphorylation at T205 from the mean in (b)(i) is 2.0 σ or below.

7 . The method of claim 1 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(i) is 1.5 σ or above, and the deviation of tau phosphorylation at T205 from the mean in (b)(i) is below 1.5 σ, and the deviation of the amount of Nfl from the mean in (b)(i) is below 1.5 σ,

wherein σ is the standard deviation defined by (1) the normal distribution of tau phosphorylation at the residue, or (2) the normal distribution of the amount of Nfl, as measured in the control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF.

8 . The method of claim 7 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(i) is 2.0 σ or above, the deviation of tau phosphorylation at T205 from the mean in (b)(i) is 2.0 σ or below.

9 . The method of claim 1 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(ii) is 1.5 σ or above, and the deviation of tau phosphorylation at T205 above the mean in (b)(ii) is 1.5 σ or above,

wherein σ is the standard deviation defined by the normal distribution of tau phosphorylation at the residue, as measured in the control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF.

10 . The method of claim 9 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(ii) is 2.0 σ or above, and the deviation of tau phosphorylation at T205 above the mean in (b)(ii) is 2.0 σ or above.

11 . The method of claim 1 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(ii) is 1.5 σ or above, and the deviation of tau phosphorylation at T205 above the mean in (b)(ii) is 1.5 σ or above, and the deviation of the amount of Nfl above the mean in (b)(ii) is 1.5 σ or above,

wherein σ is the standard deviation defined by (1) the normal distribution of tau phosphorylation at the residue, or (2) the normal distribution of the amount of Nfl, as measured in the control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF.

12 . The method of claim 11 , wherein the deviation of tau phosphorylation at T181 and/or T217 above the mean in (b)(ii) is 2.0 σ or above, the deviation of tau phosphorylation at T205 above the mean in (b)(ii) is 2.0 σ or above, and the deviation of the amount of Nfl above the mean in (b)(ii) is 2.0 σ or above.

13 . The method of claim 1 , wherein the subject is asymptomatic or has a CDR of 0.5 or less.

14 . The method of claim 1 , wherein the subject is identified as about 10 years to about 25 years, or about 10 years to about 20 years, from the onset of mild cognitive impairment due to Alzheimer's disease.

15 . The method of claim 1 , wherein the therapeutic agent is a kinase inhibitor.

16 . The method of claim 15 , wherein the kinase inhibitor inhibits a thousand-and-one amino acid kinase (TAOK), CDK, GSK-3β, MARK, CDK5, or Fyn.

17 . The method of claim 1 , wherein the therapeutic agent is a phosphatase activator.

18 . The method of claim 17 , wherein the phosphatase activator increases the activity of protein phosphatase 2A.

19 . The method of claim 1 , wherein the subject receives additional testing, wherein the additional testing is amyloid imaging by PET or tau imaging by PET.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2023
From: BATEMAN, RANDALL; BARTHELEMY, NICOLAS; MCDADE, ERIC
To: WASHINGTON UNIVERSITY
Reel/Frame 063794/0465 →
Continuity (11)
Continuation In Part 17368403 · Jul 6, 2021
Continuation 17015985 · Sep 9, 2020
Continuation In Part PCTUS2019030725 · May 3, 2019
Continuation In Part PCTUS2022015998 · Feb 10, 2022
Provisional Application 62898407 · Sep 10, 2019
Provisional Application 62666504 · May 3, 2018
Provisional Application 62666509 · May 3, 2018
Provisional Application 63158694 · Mar 9, 2021
Provisional Application 63147833 · Feb 10, 2021
Provisional Application 63197826 · Jun 7, 2021
Provisional Application 63183417 · May 3, 2021
References Cited (193)
US 7892845B2 · Bateman et al. · 2011 [cited by applicant]
US 7939313B2 · Heyduk et al. · 2011 [cited by applicant]
US 8232107B2 · Bateman et al. · 2012 [cited by applicant]
US 10830775B2 · Bateman et al. · 2020 [cited by applicant]
US 11085935B2 · Barthelemy et al. · 2021 [cited by applicant]
US 11402392B2 · Barthelemy et al. · 2022 [cited by applicant]
US 11635440B2 · Barthelemy et al. · 2023 [cited by applicant]
US 20030228259A1 · Hellerstein · 2003 [cited by applicant]
US 20080220449A1 · Vasan et al. · 2008 [cited by applicant]
US 20090104628A1 · Reagan et al. · 2009 [cited by applicant]
US 20090142766A1 · Holtzman et al. · 2009 [cited by applicant]
US 20110177509A1 · Goate et al. · 2011 [cited by applicant]
US 20110294138A1 · Bateman et al. · 2011 [cited by applicant]
US 20130115716A1 · Bateman et al. · 2013 [cited by applicant]
US 20140302520A1 · Bateman et al. · 2014 [cited by applicant]
US 20140370619A1 · Holtzman et al. · 2014 [cited by applicant]
US 20150140672A1 · Bateman et al. · 2015 [cited by applicant]
US 20150254421A1 · Bateman et al. · 2015 [cited by applicant]
US 20150370447A1 · Jitkoff · 2015 [cited by applicant]
US 20170137502A1 · Pfeifer et al. · 2017 [cited by applicant]
US 20170260263A1 · Novák et al. · 2017 [cited by applicant]
US 20170307639A1 · Bateman et al. · 2017 [cited by applicant]
US 20180372720A1 · Wildburger et al. · 2018 [cited by applicant]
US 20200400689A1 · Barthelemy et al. · 2020 [cited by applicant]
US 20210096139A1 · Bateman et al. · 2021 [cited by applicant]
US 20210341495A1 · Barthelemy et al. · 2021 [cited by applicant]
US 20250147049A1 · Bateman et al. · 2025 [cited by applicant]
CN 101124247A · 2008 [cited by applicant]
CN 104185640A · 2014 [cited by applicant]
CN 107428820A · 2017 [cited by applicant]
JP 2013535690A · 2013 [cited by applicant]
JP 2016535283A · 2016 [cited by applicant]
JP 7301394B2 · 2023 [cited by applicant]
RU 2567665C2 · 2015 [cited by applicant]
RU 2653451C2 · 2018 [cited by applicant]
WO 03068919A2 · 2003 [cited by applicant]
WO 2006107814A2 · 2006 [cited by applicant]
WO 2006133732A1 · 2006 [cited by applicant]
WO 2008140639A2 · 2008 [cited by applicant]
WO 2009062152A1 · 2009 [cited by applicant]
WO 2009076581A1 · 2009 [cited by applicant]
WO 2010056815A1 · 2010 [cited by applicant]
WO 2010065878A1 · 2010 [cited by applicant]
WO 2014160647A1 · 2014 [cited by applicant]
WO 2014161890A1 · 2014 [cited by applicant]
WO 2016054247A1 · 2016 [cited by applicant]
WO 2017053739A1 · 2017 [cited by applicant]
WO 2019213612A1 · 2019 [cited by applicant]
WO 2020146652A1 · 2020 [cited by applicant]
WO 2021050733A1 · 2021 [cited by applicant]
Albert M.S., et al., “The Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer… [cited by applicant]
Alonso A.C., et al., “Hyperphosphorylation Induces Self-Assembly of Tau into Tangles of Paired Helical Filaments/Straight Filaments,” Proceedings of the National Academy of Sciences, Jun. 5, 2001, vol. 98, No. 12, pp. 6… [cited by applicant]
Arriagada P.V., et al., “Neurofibrillary Tangles But Not Senile Plaques Parallel Duration and Severity of Alzheimer's Disease,” Neurology, Mar. 1992, vol. 42, pp. 631-639. [cited by applicant]
Augustinack J.C., et al., “Specific Tau Phosphorylation Sites Correlate with Severity of Neuronal Cytopathology in Alzheimer's Disease,” Acta Neuropathologica, Jan. 2002, vol. 103, No. 1, pp. 26-35. [cited by applicant]
Bacioglu M., et al., “Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases,” Neuron, Cell Press, Jul. 6, 2016, vol. 91, No. 1, pp. 56-66. [cited by applicant]
Barthelemy N., et al., “Profiling Alzheimer Disease Stages in Dominantly Inherited Alzheimer Disease Using CSF Tau Phosphorylation Isoforms: Position Matters,” Annals of Neurology, 2018, vol. 84, pp. S159-S160. [cited by applicant]
Barthélemy N., et al., “Mass Spectrometry Follow-Up of T181, S199, S202, T205, and T217 Tau Phosphorylation in Cerebrospinal Fluid from Patients Revealed a Specific Alzheimer's Disease Pattern,” Alzheimers Dement, The J… [cited by applicant]
Barthélemy N.R., et al., “A Soluble Phosphorylated Tau Signature Links Tau, Amyloid and the Evolution of Stages of Dominantly Inherited Alzheimer's Disease,” Nature Medicine, Mar. 2020, vol. 26, No. 3, pp. 398-407, XP03… [cited by applicant]
Barthélemy N.R., et al., “Mass Spectrometry-Based Measurement of Longitudinal CSF Tau Identifies Different Phosphorylated Sites That Track Distinct Stages of Presymptomatic Dominantly Inhereted AD,” Alzheimers Dement, T… [cited by applicant]
Barthélemy N.R., et al., “Tau Hyperphosphorylation on T217 in Cerebrospinal Fluid is Specifically Associated to Amyloid-beta Pathology,” BioRxiv, Nov. 30, 2017, pp. 1-20, 40 Pages, DOI: 10.1101/226977, XP055621444, Retr… [cited by applicant]
Barthélemy N.R., et al., “Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and are Differentially Affected by Alzheimer's Disea… [cited by applicant]
Barthélemy N.R., et al., “Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity,” Journal of Proteome … [cited by applicant]
Bateman R.J., et al., “Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease,” Published in Final Format as: The New England Journal of Medicine, Aug. 30, 2012, vol. 367, No. 9, pp. 795-804, NIH Pub… [cited by applicant]
Bateman R.J., et al., “The DIAN-TU Next Generation Alzheimer's Prevention Trial: Adaptive Design and Disease Progression Model,” Published in Final Edited Form as Alzheimers Dementia, Jan. 2017, vol. 13, No. 1, pp. 8-19… [cited by applicant]
Benjamini Y., et al., “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,” Journal of the Royal Statistical Society Series B, 1995, vol. 57, No. 1, pp. 289-300. [cited by applicant]
Benzinger T.L.S., et al., “Regional Variability of Imaging Biomarkers in Autosomal Dominant Alzheimer's Disease,” Proceedings of the National Academy of Sciences of the United States of America, Nov. 5, 2013, vol. 110, … [cited by applicant]
Biernat J., et al., “Phosphorylation of Ser262 Strongly Reduces Binding of Tau to Microtubules: Distinction Between PHF-like Immunoreactivity and Microtubule Binding,” Neuron, Jul. 1993, vol. 11, No. 1, pp. 153-163. [cited by applicant]
Bogoslovsky T., et al., “Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid Beta up to 90 Days after Traumatic Brain Injury,” Journal of Neurotrauma, Jan. 1, 2017, vol. 34, No. 1, pp. 66-73. [cited by applicant]
Braak H., et al., “Staging of Alzheimer's Disease-related Neurofibrillary Changes,” Neurobiology of Aging, May-Jun. 1995, vol. 16, No. 3, pp. 271-278. [cited by applicant]
Bros P., et al., “Antibody-free Quantification of Seven Tau Peptides in Human CSF Using Targeted Mass Spectrometry,” Frontiers in Neuroscience, Sep. 1, 2015, vol. 9, Article No. 302, pp. 1-8, DOI:10.3389/fnins.2015.0030… [cited by applicant]
Buerger K., et al., “CSF Phosphorylated Tau Protein Correlates with Neocortical Neurofibrillary Pathology in Alzheimer's Disease,” Brain, Dec. 2006, vol. 129, pp. 3035-3041. [cited by applicant]
Bulut M., et al., “Tau Protein as a Serum Marker of Brain Damage in Mild Traumatic Brain Injury: Preliminary Results,” Advances in Therapy, Jan./Feb. 2006, vol. 23, No. 1, pp. 12-22. [cited by applicant]
Chung P.J., et al., “Tau Mediates Microtubule Bundle Architectures Mimicking Fascicles of Microtubules Found in the Axon Initial Segment,” Nature Communications, Jul. 25, 2016, vol. 7, Article No. 12278, pp. 1-9. [cited by applicant]
Cicognola C., et al., “Novel Tau Fragments in Cerebrospinal Fluid: Relation to Tangle Pathology and Cognitive Decline in Alzheimer's Disease,” Acta Neuropathologica (Berl), Springer, Feb. 2019, vol. 137, No. 2, pp. 279-… [cited by applicant]
Cohen A.D., et al., “Early Striatal Amyloid Deposition Distinguishes Down Syndrome and Autosomal Dominant Alzheimer's Disease from Late Onset Amyloid Deposition,” Published in Final Edited Form as: Alzheimer's and Demen… [cited by applicant]
Cross D., et al., “Tau-like Proteins Associated with Centrosomes in Cultured Cells,” Experimental Cell Research, Dec. 15, 1996, vol. 229, No. 2, pp. 378-387. [cited by applicant]
Crowther R.A., “Straight and Paired Helical Filaments in Alzheimer Disease Have a Common Structural Unit,” Proceedings of the National Academy of Sciences, Mar. 1991, vol. 88, pp. 2288-2292. [cited by applicant]
Darlix A., et al., “The Prognostic Value of the Tau Protein Serum Level in Metastatic Breast Cancer Patients and its Correlation with Brain Metastases,” BMC Cancer, Published Online on Jan. 30, 2019, vol. 19, No. 1, Art… [cited by applicant]
Despres C., et al., “Identification of the Tau Phosphorylation Pattern that Drives its Aggregation,” Proceedings of the National Academy of Sciences, Aug. 22, 2017, vol. 114, No. 34, pp. 9080-9085. [cited by applicant]
Examination Report for United Arab Emirates Patent Application No. P6001522/2020, mailed on Dec. 16, 2023, 8 pages. [cited by applicant]
Extended European Search Report for European Application No. 15846448.7, mailed Apr. 12, 2018, 6 Pages. [cited by applicant]
Extended European Search Report for European Application No. 19797038.7, mailed Jan. 17, 2022, 10 Pages. [cited by applicant]
Extended European Search Report for European Application No. 20863858.5, mailed on Mar. 14, 2023, 9 pages. [cited by applicant]
Fagan A.M., et al., “Cerebrospinal Fluid tau/beta-amyloid 42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults,” Archieves of Neurology, Mar. 2007, vol. 64, No. 3, pp. 343-349. [cited by applicant]
Fagan A.M., et al., “Inverse Relation Between in Vivo Amyloid Imaging Load and Cerebrospinal Fluid Alpha beta42 in Humans,” Annals of Neurology, Mar. 2006, vol. 59, No. 3, pp. 512-519. [cited by applicant]
Fagan A.M., et al., “Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease,” Science Translational Medicine, Mar. 5, 2014, vol. 6, No. 226, 226ra30, 35 Pages. [cited by applicant]
First Office Action and Search Report for Chinese Patent Application No. 201980030025.7, dated Nov. 4, 2022, 14 pages. [cited by applicant]
Fitzpatrick A.W.P., et al., “Cryo-EM Structures of Tau Filaments from Alzheimer's Disease Brain,” Published as Nature, Jul. 13, 2017, vol. 547, No. 7662, pp. 185-190, HHS Public Access Author Manuscript, Jan. 5, 2018, p… [cited by applicant]
Fleisher A.S., et al., “Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: A Cross-sectional Study,” JAMA Neurology, Mar. 1, 2015, vol. 72, No. 3, pp. 316-324… [cited by applicant]
Funk K.E., et al., “Lysine Methylation is an Endogenous Post-Translational Modification of Tau Protein in Human Brain and a Modulator of Aggregation Propensity,” Biochemical Journal, Aug. 15, 2014, vol. 462, No. 1, pp. … [cited by applicant]
Gallien S., et al., “Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer,” Molecular Cellular Proteomics, Sep. 7, 2012, vol. 11, No. 12, pp. 1709-1723. [cited by applicant]
Gallien S., et al., “Technical Considerations for Large-scale Parallel Reaction Monitoring Analysis,” Journal of Proteomics, Apr. 2014, vol. 100 pp. 147-159. [cited by applicant]
Geyer P.E., et al., “Revisiting Biomarker Discovery by Plasma Proteomics,” Molecular Systems Biology, Sep. 26, 2017, vol. 13, No. 942, pp. 1-15. [cited by applicant]
Gillette M.A., et al., “Quantitative Analysis of Peptides and Proteins in Biomedicine by Targeted Mass Spectrometry,” Nature Methods, Jan. 2013, vol. 10, No. 1, pp. 28-34, 12 Pages. [cited by applicant]
Goedert M., et al., “Multiple Isoforms of Human Microtubule-associated Protein Tau: Sequences and Localization in Neurofibrillary Tangles of Alzheimer's disease,” Neuron, Oct. 1989, vol. 3, pp. 519-526. [cited by applicant]
Gordon B., et al., “Tau PET in Autosomal Dominant Alzheimer Disease: Relationship to Cognition, Dementia And Biomarkers,” Brain, Apr. 1, 2019, vol. 142, No. 4, pp. 1063-1076. [cited by applicant]
Gordon B.A. et al., “Spatial Patterns of Neuroimaging Biomarker Change in Individuals from Families with Autosomal Dominant Alzheimer's Disease: A Longitudinal Study,” The Lancet, Neurology, Feb. 2018, vol. 7, pp. 241-2… [cited by applicant]
Grundke-Iqbal I., et al., “Abnormal Phosphorylation of the Microtubule-Associated Protein Tau (Tau) in Alzheimer Cytoskeletal Pathology,” Proceedings of the National Academy of Sciences of the United States of America, … [cited by applicant]
Hampel H., et al., “Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease: A Comparative Cerebrospinal Fluid Study,” Archives of General Psychiatry, Jan. 2004, vol. 61, pp. 95-102. [cited by applicant]
Hanger D.P., et al., “New Phosphorylation Sites Identified in Hyperphosphorylated Tau (Paired Helical Filament-Tau) from Alzheimer's Disease Brain Using Nanoelectrospray Mass Spectrometry,” Journal of Neurochemistry, De… [cited by applicant]
Patterson B.W., et al., “Age and Amyloid Effects on Human Central Nervous System Amyloid-Beta Kinetics,” Annals of Neurology, Sep. 2015, vol. 78, No. 3, pp. 439-453. [cited by applicant]
Peterson A.C., et al., “Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics,” Molecular Cellular Proteomics, Nov. 2012, vol. 11, No. 11, pp. 1475-1488. [cited by applicant]
Potter R., et al., “Increased in Vivo Amyloid-B42 Production, Exchange, and Irreversible Loss in Presenilin Mutations Carriers,” Published in Final Format as: Science Translational Medicine Jun. 12, 2013, vol. 5, No. 18… [cited by applicant]
Preische O., et al., “Serum Neurofilament Dynamics Predicts Neurodegeneration and Clinical Progression in Presymptomatic Alzheimer's Disease,” Nature Medicine, Feb. 2019, vol. 25, No. 2, pp. 277-283, 27 pages. [cited by applicant]
Price J.L., et al., “Tangles and Plaques in Nondemented Aging and “Preclinical” Alzheimer's Disease,” Annals of Neurology, Mar. 1999, vol. 45, No. 3, pp. 358-368. [cited by applicant]
Price J.L., et al., “The Distribution of Tangles, Plaques and Related Immunohistochemical Markers in Healthy Aging and Alzheimer's Disease,” Neurobiology of Aging, Jul.-Aug. 1991, vol. 12, No. 4, pp. 295-312. [cited by applicant]
Qian J., et al., “Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design,” JAMA Neurology, May 1, 2017, vol. 74, No. 5, … [cited by applicant]
Quiroz Y.T., et al., “Association Between Amyloid and Tau Accumulation in Young Adults with Autosomal Dominant Alzheimer Disease,” JAMA Neurology, May 2018, vol. 75, No. 5, pp. 548-556, 17 pages. [cited by applicant]
Quiroz Y.T., et al., “Cortical Atrophy in Presymptomatic Alzheimer's Disease Presenilin 1 Mutation Carriers,” Journal of Neurology, Neurosurgery and Psychiatry, May 2013, vol. 84, No. 5, pp. 556-561., 13 pages. [cited by applicant]
Ridha B.H., et al., “Tracking Atrophy Progression in Familial Alzheimer's Disease: A Serial MRI Study,” Lancet Neurology, Oct. 2006, vol. 5, pp. 828-834. [cited by applicant]
Roberts K.F., et al., “Amyloid-β Efflux from the Central Nervous System into the Plasma,” Annals of Neurology, Dec. 2014, vol. 76, No. 6, pp. 837-844. [cited by applicant]
Rubenstein R., et al., “Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers,” JAMA Neurology, Sep. 2017, vol. 74, No. 9, pp. 1063-1072, 20 page… [cited by applicant]
Russell C.L., et al., “Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates,” Journal of Alzheimer's Disease, 2017, vo… [cited by applicant]
Ryman D.C., et al., “Symptom Onset in Autosomal Dominant Alzheimer Disease,” A Systematic Review and Meta-analysis, Neurology, Jul. 15, 2014, vol. 83, pp. 253-260. [cited by applicant]
Saman S., et al., “Exosome-associated Tau Is Secreted in Tauopathy Models and is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease,” Journal of Biological Chemistry, Feb. 3, 2012, vol. 287, No… [cited by applicant]
Sato C., et al., “Tau Kinetics in Neurons and the Human Central Nervous System,” Neuron, Mar. 21, 2018, vol. 97, No. 6, e7, pp. 1284-1298. [cited by applicant]
Schelle J., et al., “Prevention of Tau Increase in Cerebrospinal Fluid of App Transgenic Mice Suggests Downstream Effect of BACE1 Inhibition,” Alzheimer's Dementia: The Journal of the Alzheimer's Association, Jun. 2017,… [cited by applicant]
Schindler S.E., et al., “High-Precision Plasma Beta-amyloid 42/40 Predicts Current and Future Brain Amyloidosis,” Neurology, Oct. 22, 2019, vol. 93, No. 17, pp. e1647-e1659. [cited by applicant]
Schneider A., et al., “Tau-Based Treatment Strategies in Neurodegenerative Diseases,” Neurotherapeutics, Jul. 2008, vol. 5, No. 3, pp. 443-457. [cited by applicant]
Scholl M., et al., “PET Imaging of Tau Deposition in the Aging Human Brain,” Neuron, Mar. 2, 2016, vol. 89, No. 5, pp. 971-982, 26 pages. [cited by applicant]
Search Report for United Arab Emirates Patent Application No. P6001522/2020, mailed on Dec. 16, 2023, 4 pages. [cited by applicant]
Second Office Action and Search Report for Chinese Patent Application No. 201980030025.7, dated Oct. 28, 2023, 14 pages. [cited by applicant]
Sparks D.L., et al., “Tau is Reduced in AD Plasma and Validation of Employed ELISA Methods,” American Journal of Neurodegenerative Disease : AJND, E-Century Publishing, Madison (Wisconsin), May 30, 2012, vol. 1, No. 1, … [cited by applicant]
Sperling R.A., et al., “Toward Defining the Preclinical Stages of Alzheimer's Disease: Recommendations from the National Institute on Aging—Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Dis… [cited by applicant]
Storandt M., et al., “Clinical and Psychological Characteristics of the Initial Cohort of the Dominantly Inherited Alzheimer Network (DIAN),” Neuropsychology, Jan. 2014, vol. 28, No. 1, pp. 19-29, 22 pages. [cited by applicant]
Su Y., et al., “Partial Volume Correction in Quantitative Amyloid Imaging,” Neuroimage, Feb. 15, 2015, vol. 107, pp. 55-64, 24 pages, DOI: 10.1016/j.neuroimage.2014.11.058. [cited by applicant]
Tatebe H., et al., “Quantification of Plasma Phosphorylated Tau to Use as a Biomarker for Brain Alzheimer Pathology: Pilot Case-control Studies Including Patients with Alzheimer's Disease and Down Syndrome,” Molecular N… [cited by applicant]
Thomas S.N., et al., “Dual Modification of Alzheimer's Disease PHF-Tau Protein by Lysine Methylation and Ubiquitylation: A Mass Spectrometry Approach,” Acta Neuropathologica, 2012, vol. 123, No. 1, pp. 105-117. [cited by applicant]
Toledo J.B., et al., “Longitudinal Change in CSF Tau and A beta Biomarkers for up to 48 Months in ADNI,” Acta Neuropathol, Nov. 2013, vol. 126, No. 5, pp. 659-670, 19 pages. [cited by applicant]
Vandermeeren M., et al., “Detection of Tau Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-linked Immunosorbent Assay,” Journal of Neurochemistry, Nov. 1993, vol. 61, No. … [cited by applicant]
Villemagne V.L., et al., Tau Imaging: Early Progress and Future Directions, The Lancet, Neurology, Jan. 2015, vol. 14, No. 1, pp. 114-124. [cited by applicant]
Voronkov M., et al., “Phosphoprotein Phosphatase 2A: A Novel Druggable Target for Alzheimer's Disease,” Published in Final Edited Form as: Future Medicinal Chemistry, May 2011, pp. 821-833, NIH Public Access Author Manu… [cited by applicant]
Wang Y., et al., “Tau in Physiology and Pathology,” Nature Reviews, Neuroscience, Jan. 2016, vol. 17, No. 1, pp. 5-21. [cited by applicant]
Xiong C., et al., “Longitudinal Relationships Among Biomarkers for Alzheimer Disease in the Adult Children Study,” Neurology, Apr. 19, 2016, vol. 86, pp. 1499-1506. [cited by applicant]
Yamada K., et al., “In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice,” The Journal of Neuroscience, Sep. 14, 2011, vol. 31, No. 37, pp. 13110… [cited by applicant]
Yamada K., et al., “Neuronal Activity Regulates Extracellular Tau in Vivo,” The Journal of Experimental Medicine, Mar. 10, 2014, vol. 211, No. 3, pp. 387-393, E-Published on Feb. 17, 2014, DOI: 10.1084/jem.20131685. [cited by applicant]
Yanamandra K., et al., “Anti-Tau Antibodies that Block Tau Aggregate Seeding in Vitro Markedly Decrease Pathology and Improve Cognition in Vivo,” Neuron, Oct. 16, 2013, vol. 80, No. 2, pp. 402-414. [cited by applicant]
Zempel H., et al., “Aβ Oligomers Cause Localized Ca(2+) Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines,” The Journal of Neuroscience, Sep. 8, 2010… [cited by applicant]
Zetterberg H., et al., “Plasma Tau Levels in Alzheimer's Disease,” Alzheimer's Research and Therapy, Mar. 28, 2013, vol. 5, No. 9, pp. 1-3. [cited by applicant]
Zetterberg H., “Review: Tau in Biofluids-Relation to Pathology, Imaging and Clinical Features,” Neuropathology and Applied Neurobiology, Apr. 2017, vol. 43, No. 3, pp. 194-199. [cited by applicant]
Decision on Rejection for Chinese Patent Application No. 201980030025.7, mailed on Jan. 18, 2024, 9 pages. [cited by applicant]
Non Final Office Action for U.S. Appl. No. 17/843,470 mailed on Aug. 11, 2022, 9 Pages. [cited by applicant]
Office Action and Search Report for Russian Patent Application No. 2022106031, dated Feb. 15, 2024, 32 pages. [cited by applicant]
Hanger D.P., et al., “Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis,” The Journal of Biological Chemistry, Aug. 10, 2007, vol. 282, No. 32, pp. 23645-… [cited by applicant]
Hasegawa M., et al., “Protein Sequence and Mass Spectrometric Analyses of Tau in the Alzheimer's Disease Brain,” The Journal of Biological Chemistry, Aug. 25, 1992, vol. 267, No. 24, pp. 17047-17054. [cited by applicant]
He Z., et al., “Amyloid-beta Plaques Enhance Alzheimer's Brain Tau-seeded Pathologies by Facilitating Neuritic Plaque Tau Aggregation,” Nature Medicine, Jan. 2018, vol. 24, No. 1, pp. 29-38. [cited by applicant]
Hu W.T., et al., “Reduced CSF p-Tau181 to Tau Ratio is a Biomarker for FTLD-TDP,” Neurology, Nov. 26, 2013, vol. 81, pp. 1945-1952. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/030725, mailed Nov. 12, 2020, 41 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/050208, mailed Mar. 24, 2022 09 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2015/053283, mailed Jan. 22, 2016, 10 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/030725, mailed Aug. 28, 2019, 45 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/050208, mailed Dec. 22, 2020, 12 Pages. [cited by applicant]
Iqbal K., et al., “Tau in Alzheimer Disease and Related Tauopathies,” Published in Final Edited Form as: Current Alzheimer Research, Dec. 2010, vol. 7, No. 8, pp. 656-664, NIH Public Access Author Manuscript, available … [cited by applicant]
Iqbal K., et al., “Tau Pathology in Alzheimer Disease and Other Tauopathies,” Biochimica et Biophysica Acta, Jan. 3, 2005, vol. 1739. pp. 198-210. [cited by applicant]
Ittner A., et al., “Site-specific Phosphorylation of Tau Inhibits Amyloid-beta Toxicity in Alzheimer's Mice,” Science, Nov. 18, 2016, vol. 354, No. 6314, 06 Pages. [cited by applicant]
Ittner L.M., et al., “Dendritic Function of Tau Mediates Amyloid-beta Toxicity in Alzheimer's Disease Mouse Models,” Cell, Aug. 6, 2010, vol. 142, pp. 387-397. [cited by applicant]
Jack C.R. Jr., et al., “A/T/N: An Unbiased Descriptive Classification Scheme for Alzheimer Disease Biomarkers,” Neurology, Aug. 2, 2016, vol. 87, pp. 539-547. [cited by applicant]
Jack C.R. Jr., et al., “NIA-AA Research Framework: Toward a Biological Definition of Alzheimer's Disease,” Alzheimers and Dementia, Apr. 2018, vol. 14, No. 4, pp. 535-562. [cited by applicant]
Jin M., et al., “Soluble Amyloid β-protein Dimers Isolated from Alzheimer Cortex Directly Induce Tau Hyperphosphorylation and Neuritic Degeneration,” Proceedings of the National Academy of Sciences, Apr. 5, 2011, vol. 1… [cited by applicant]
Johnson K.A., et al., “Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education,” Journal of Nuclear Medicine, Jul. 2013, vol. 54, No. 7, pp. 1011-1013. [cited by applicant]
Kanmert D., et al., “C-Terminally Truncated Form of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death,” The Journal of Neuroscience, Jul. 29, 2015, vol. 35, … [cited by applicant]
Karch C.M., et al., “Extracellular Tau Levels are Influenced by Variability in Tau that is Associated with Tauopathies,” The Journal of Biological Chemistry, Dec. 14, 2012, vol. 287, No. 51, pp. 42751-42762. [cited by applicant]
Kasai T., et al., “Increased Levels of Plasma Total Tau in Adult Down Syndrome,” PLOS ONE, Nov. 30, 2017, vol. 12, No. 11, 12 Pages, doi: 10.1371/journal.pone.0188802. [cited by applicant]
Kimura T., et al., “Phospho-Tau Bar Code: Analysis of Phosphoisotypes of Tau and Its Application to Tauopathy,” Frontiers in Neuroscience, Feb. 6, 2018, vol. 12, No. 44, pp. 1-9. [cited by applicant]
Klunk W.E., et al., “Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B,” Annals of Neurology, Mar. 2004, vol. 55, No. 3, pp. 306-319. [cited by applicant]
Köpke E., et al., “Microtubule-associated Protein Tau, Abnormal Phosphorylation of a Non-paired Helical Filament Pool in Alzheimer Disease,” The Journal of Biological Chemistry, Nov. 15, 1993, vol. 268, No. 32, pp. 2437… [cited by applicant]
Lim Y.Y., et al., “BDNF Va166Met Moderates Memory Impairment, Hippocampal Function and Tau in Preclinical Autosomal Dominant Alzheimer's Disease,” Brain: A Journal of Neurology, Oct. 2016, vol. 139, pp. 2766-2777. [cited by applicant]
Liu W-K., et al., “Application of Synthetic Phospho- and Unphospho-Peptides to Identify Phosphorylation Sites in a Subregion of the Tau Molecule, which is Modified in Alzheimer's Disease,” Journal of Neuroscience Resear… [cited by applicant]
Luo J., et al., “Bivariate Correlation Coefficients in Family-type Clustered Studies” Biometrical Journal, Nov. 2015, vol. 57, No. 6, pp. 1084-1109, 32 p. [cited by applicant]
Maia L.F., et al., “Changes in Amyloid-beta and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein,” Science Translation Medicine, Jul. 17, 2013, vol. 5, No. 194: 194re192, 8 Page… [cited by applicant]
Mair W., et al., “FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro And in Human Disease,” Analytical Chemistry, Apr. 5, 2016, vol. 88, No. 7, pp. 3704-3714, XP055371662. [cited by applicant]
Malia T.J., et al., “Epitope Mapping and Structural Basis for the Recognition of Phosphorylated Tau by the Anti-tau Antibody AT8,” Proteins: Structure, Function and Bioinformatics, Apr. 2016, vol. 84, pp. 427-434. [cited by applicant]
Matsuo E.S., et al., “Biopsy-derived Adult Human Brain Tau is Phosphorylated at Many of the Same Sites as Alzheimer's Disease Paired Helical Filament Tau,” Neuron, Oct. 1994, vol. 13, pp. 989-1002. [cited by applicant]
Mattsson N., et al., “Plasma Tau in Alzheimer Disease,” Neurology, Oct. 25, 2016, vol. 87, No. 17, pp. 1827-1835. [cited by applicant]
Mawuenyega K.G., et al., “Amyloid-beta Isoform Metabolism Quantitation by Stable Isotope-labeled Kinetics,” Analytical Biochemistry, Sep. 1, 2013, vol. 440, No. 1, pp. 56-62, E-Published on May 25, 2013, DOI: 10.1016/j.… [cited by applicant]
McDade E., et al., “Longitudinal Cognitive and Biomarker Changes in Dominantly Inherited Alzheimer Disease,” Neurology, Oct. 2, 2018, vol. 91, No. 14, pp. e1295-e1306. [cited by applicant]
McKhann G.M., et al., “The Diagnosis Of Dementia Due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease,” Pub… [cited by applicant]
Medina M., et al., “Further Understanding of Tau Phosphorylation: Implications for Therapy,” Expert Review of Neurotherapeutics, Jan. 2015, vol. 15, No. 1, pp. 115-122. [cited by applicant]
Mielke M.M., et al., “Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging,” JAMA Neurology, Sep. 2017, vol. 74, No. 9, pp. 107… [cited by applicant]
Mielke M.M., et al., “Plasma Phospho-Tau181 Increases with Alzheimer's Disease Clinical Severity and is Associated with Tau- and Amyloid-positron Emission Tomography,” Alzheimers and Dementia, Aug. 2018, vol. 14, No. 8,… [cited by applicant]
Morris J.C., et al., “Developing an International Network for Alzheimer Research: The Dominantly Inherited Alzheimer Network,” Clinical Investigation, Oct. 1, 2012, vol. 2, No. 10, pp. 975-984, 17 pages. [cited by applicant]
Morris J.C., “The Clinical Dementia Rating (CDR): Current Version and Scoring Rules,” Neurology, Nov. 1993, vol. 43, pp. 2412-2414. [cited by applicant]
Morris M., et al., “Tau Post-translational Modifications in Wild-type and Human Amyloid Precursor Protein Transgenic Mice,” Nature Neuroscience, Aug. 2015, vol. 18, No. 8, pp. 1183-1189. [cited by applicant]
Nakamura A., et al., “High Performance Plasma Amyloid-β Biomarkers for Alzheimer's Disease,” Nature, Feb. 8, 2018, vol. 554, No. 7691, pp. 249-254. [cited by applicant]
Neddens J., et al., “Phosphorylation of Different Tau Sites During Progression of Alzheimer's Disease,” Acta Neuropathogica Communications, Jun. 29, 2018, vol. 6, No. 52, pp. 1-15. [cited by applicant]
Neselius S., et al., “Olympic Boxing is Associated with Elevated Levels of the Neuronal Protein Tau in Plasma,” Brain Injury, Apr. 2013, vol. 27, No. 4, pp. 425-433. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/015,985 mailed Mar. 24, 2021, 12 pages. [cited by applicant]
Office Action and Search Report for Russian Patent Application No. 2020138244, dated Oct. 18, 2022, 19 pages. [cited by applicant]
Office Action for Canadian Application No. 2,962,969, mailed Oct. 29, 2021, 3 pages. [cited by applicant]
Office Action for Japanese Application No. 2020-561809, mailed on Jun. 6, 2023, 3 Pages. [cited by applicant]
Office Action for South African Application No. 2020/06348, dated Oct. 26, 2021, 1 Page. [cited by applicant]
Office Action for U.S. Appl. No. 17/015,985, mailed Nov. 19, 2020, 12 Pages. [cited by applicant]
Ovod V., et al., “Amyloid β Concentrations and Stable Isotope Labeling Kinetics of Human Plasma Specific to Central Nervous System Amyloidosis,” Alzheimer's Dementia, Aug. 2017, vol. 13, No. 8, pp. 841-849. [cited by applicant]